Navigation Links
Labopharm to host webcast presentation on novel trazodone formulation - tomorrow (Dec.16/08) at 10:00 a.m. ET
Date:12/15/2008

(SARI), for the treatment of major depressive disorder (MDD) to address patient needs in the current depression landscape, providing an effective and convenient treatment option. In a Phase III placebo controlled study of patients with MDD, Labopharm's novel trazodone formulation demonstrated antidepressant efficacy, including rapid onset of therapeutic response, improved overall quality of sleep, a well tolerated adverse event profile, a very low rate of sexual dysfunction and no weight gain compared to placebo.

MDD is one of the most prevalent central nervous system disorders, affecting more than 120 million people worldwide. In 2007, the global market for antidepressants and related psychiatric drugs was US$19 billion, of which US$12 billion was accounted for by the U.S.

About Labopharm Inc.

Labopharm is an emerging leader in optimizing the performance of existing small molecule drugs using its proprietary controlled-release technologies. The Company's lead product, a unique once-daily formulation of tramadol, is being commercially launched in key markets globally and its second product, a novel formulation of trazodone for the treatment of major depressive disorder, is under regulatory review by the FDA. The Company also has a robust pipeline of follow-on products in both pre-clinical and clinical development. Labopharm's vision is to become an integrated, international, specialty pharmaceutical company with the capability to internally develop and commercialize its own products. For more information, please visit www.labopharm.com.

This press release contains forward-looking statements, which reflect the Company's current expectations regarding future events. The forward-looking statements involve risks and uncertainties. Actual events could differ materially from those projected herein and depend on a number of factors, including the u
'/>"/>

SOURCE Labopharm Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine news :

1. Labopharm To Present Poster On Onset Of Analgesic Effect Of Once-Daily Tramadol At Congress Of The European Society Of Regional Anaesthesia And Pain Therapy
2. Labopharm provides update on U.S. regulatory process for once-daily Tramadol
3. Labopharm completes enrolment for Phase III clinical study for its once-daily trazodone antidepressant drug
4. Labopharm appeals FDAs decision on once-daily tramadol
5. Labopharm to host conference call Friday, November 9, 2007 at 8:30 a.m. (ET)
6. Labopharm to present at CIBC World Markets 18th Annual Healthcare Conference
7. Labopharm Reports Results for Third Quarter Fiscal 2007
8. Labopharm receives FDA response to appeal of Approvable Letter for once-daily tramadol
9. Labopharm enters into licensing and distribution agreement for once-daily tramadol in Australia with iNova
10. Canadian Marketing and Sales Effort for Labopharms Once-Daily Tramadol Product to Expand Significantly
11. Labopharm Reports Positive Results for Phase III Study on Once-daily Trazodone
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/1/2014)... Familylifeinsurancequotes.org has released a new blog ... citizens. , Senior citizens can qualify for affordable ... to seniors who are over 50 years old. Some ... a medical examination. , Term life insurance with a ... can qualify. Having life insurance during retirement is important ...
(Date:10/1/2014)... CA (PRWEB) October 01, 2014 Bedros ... Fit Body Boot Camp fitness boot camps, he’s also ... personal training , with sold out business summits, a ... as marketing consultant to a recent Spike TV reality ... says that now is the time for personal trainers ...
(Date:10/1/2014)... Hillsboro, Oregon (PRWEB) October 01, 2014 ... curing solutions , continues to expand the business worldwide. ... engineering along with additional capacity for manufacturing efforts. The ... over the last five years and expects this growth ... UV LED curing technology gains worldwide adoption. , ...
(Date:10/1/2014)... MO (PRWEB) October 01, 2014 Join the ... Castlewood Eating Disorder Treatment Center’s first ever charity golf tournament ... for people with eating disorders who cannot afford treatment. The ... Golf Club in Eureka, Mo. , The day-long event ... noon. A reception and award dinner will begin at 5 ...
(Date:10/1/2014)... October 01, 2014 Between 23 million ... the U.S., according to figures from the National Institutes ... Association (AARDA), and many of them have something else ... having undiagnosed celiac disease. Gluten Free Therapeutics, makers ... of undiagnosed celiac disease by publishing a series of ...
Breaking Medicine News(10 mins):Health News:Affordable Term Life Insurance - Senior Citizens Can Qualify for Coverage! 2Health News:Bedros Keuilian Shares Tips on Selling Personal Training for the Holidays 2Health News:Bedros Keuilian Shares Tips on Selling Personal Training for the Holidays 3Health News:Phoseon Technology Continues to Drive Growth Worldwide 2Health News:Project HEAL Benefit Golf Tournament Gaining Momentum 2Health News:Project HEAL Benefit Golf Tournament Gaining Momentum 3Health News:Informative New Blog Series Underscores Link Between Celiac Disease and Other Autoimmune Disorders 2Health News:Informative New Blog Series Underscores Link Between Celiac Disease and Other Autoimmune Disorders 3
... Financial contracts to care for sick or aging relatives ... new interest as everyday Americans wrestle with the time and ... legal expert says. , Law professor Richard L. Kaplan says ... a groundswell, and most people still bristle at the notion ...
... 27 Warner Chilcott Limited (Nasdaq: WCRX ) ... has filed for standard review the new drug application (NDA) ... NDA for WC 3016 was submitted by its subsidiary, Warner ... Warner Chilcott , Warner Chilcott is a leading ...
... Today, the Children,s Health Fund (CHF) announced a ... support a new health care clinic in the South ... Starr International Foundation grant will support the clinic,s medical ... The homeless health care clinic is part of the ...
... Inc. (OTC Bulletin Board: NVLX), an emerging healthcare ... distribute Infinitink (the world,s first permanent tattoo ink ... Zealand. The distribution agreement grants Jayhur Enterprises (Sydney, ... market, distribute and sell ...
... Kandahar, Afghanistan could help surgeons prepare for civilian disasters, ... two tours at the hospital. Dr. Vivian McAlister ... the Schulich School of Medicine & Dentistry at The ... the London Health Sciences Centre. He spent two months ...
... can lead to healthier livesST. LOUIS, May 27 ... rollout a new consumer health tool that will complement ... customers. Nurse Response will offer the Healthwise Knowledgebase, an ... Response consumers to access over 7,000 health topics online. ...
Cached Medicine News:Health News:Contracts adding legal twist to family health care 2Health News:Contracts adding legal twist to family health care 3Health News:Warner Chilcott Announces FDA Acceptance of NDA Submission for Low Dose Oral Contraceptive 2Health News:Warner Chilcott Announces FDA Acceptance of NDA Submission for Low Dose Oral Contraceptive 3Health News:Children's Health Fund Receives $500,000 from the Starr International Foundation to Support South Bronx Homeless Health Care Clinic 2Health News:Nuvilex Signs Agreement with Jayhur Enterprises to Distribute Infinitink - the World's First Permanent, But Easier to Remove Tattoo Ink - in Australia and New Zealand 2Health News:Nuvilex Signs Agreement with Jayhur Enterprises to Distribute Infinitink - the World's First Permanent, But Easier to Remove Tattoo Ink - in Australia and New Zealand 3Health News:Sharing surgical lessons from the Canadian field hospital in Afghanistan 2
(Date:10/1/2014)... Oct. 1, 2014  Express Scripts (NASDAQ: ... 2015 Express Scripts Medicare ® Prescription Drug Plans ... Walgreens (NYSE: WAG ) (NASDAQ: ... and clinical support  for their Medicare dollars. ... Value or Choice plans for ...
(Date:10/1/2014)... 1, 2014 Ardelyx, Inc. (NASDAQ: ... company focused on cardio-renal, gastrointestinal and metabolic ... 371 patient Phase 2b clinical trial evaluating ... syndrome (IBS-C).  Results from this study demonstrated ... IBS-C symptoms for tenapanor-treated patients compared to ...
(Date:9/30/2014)... , Sept. 30, 2014 /CNW/ - Protecting the health and safety ... Health Canada uses the appropriate powers and tools at its disposal ... safety and quality standards. To that end, Health ... stop the import into Canada of all ... . They are: , Apotex Pharmachem India Pvt ...
Breaking Medicine Technology:Express Scripts Collaborates with Walgreens to Create Value-Driven Medicare Prescription Drug Plan Pharmacy Network 2Express Scripts Collaborates with Walgreens to Create Value-Driven Medicare Prescription Drug Plan Pharmacy Network 3Express Scripts Collaborates with Walgreens to Create Value-Driven Medicare Prescription Drug Plan Pharmacy Network 4Ardelyx Reports Positive Results from Its Phase 2b Clinical Trial Evaluating Tenapanor in IBS-C Patients 2Ardelyx Reports Positive Results from Its Phase 2b Clinical Trial Evaluating Tenapanor in IBS-C Patients 3Ardelyx Reports Positive Results from Its Phase 2b Clinical Trial Evaluating Tenapanor in IBS-C Patients 4Ardelyx Reports Positive Results from Its Phase 2b Clinical Trial Evaluating Tenapanor in IBS-C Patients 5Ardelyx Reports Positive Results from Its Phase 2b Clinical Trial Evaluating Tenapanor in IBS-C Patients 6Statement by the Honourable Rona Ambrose on the import ban of drug products from three plants in India 2
... International Corporation (NASDAQ: PRXL ), a leading ... provide a live webcast of its Investor Day on ... p.m. (EDT). All interested parties are invited ... von Rickenbach, Chief Financial Officer Jim Winschel and five ...
... - Atu027, a First in Class RNAi Therapy, Demonstrates ... Possible Biomarker Identified Silence Therapeutics to Announce New ... At 2012 ASCO Annual Meeting Silence Therapeutics plc ... interference (RNAi) therapeutics company, today announces that top line data ...
Cached Medicine Technology:Parexel Invites Public To Listen To Live Webcast Of Its Investor Day May 31, 2012 2New Data from Silence's Atu027 Anticancer Trial Published at ASCO 2New Data from Silence's Atu027 Anticancer Trial Published at ASCO 3New Data from Silence's Atu027 Anticancer Trial Published at ASCO 4New Data from Silence's Atu027 Anticancer Trial Published at ASCO 5
... Our popular Back-Aid Apron ... improved Universal Back-Saver Belt that ... take more weight off your ... shoulder strap redistribute weight from ...
Freedom of movement - plus full circle, maximum radiation protection. No other full circle radiation protection design approaches the level of comfort of the VestSkirt, which divides weight between t...
... Cryo System is the first in portability and performance. ... surgeons who need a flexible, portable system with the ... CTU attaches easily to an "E" size tank and ... cryo to where it is needed.,The CTU Travel Case ...
... System is an easy-to-use, workflow-based system designed to ... Inspirex consists of the SleepWorks software and either ... and durable systems can be used for a ... - including full EEG recording - and have ...
Medicine Products: